SCHEMBL22284255

SCHEMBL22284255

Cc1ccc(C(C)NC(=O)c2nc3cc4c(-c5ccncc5)nn(C(c5ccccc5)(c5ccccc5)c5ccccc5)c4cc3[nH]2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 1/20 0.39
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK1 P28482 6/20 0.38
ROCK2 O75116 3/20 0.38
RPS6KA5 O75582 1/20 0.38
MAP4K4 O95819 1/20 0.38
CDK1 P06493 1/20 0.38
CSF1R P07333 1/20 0.38
PRKACA P17612 1/20 0.38
FLT1 P17948 1/20 0.38
RPS6KB1 P23443 1/20 0.38
CDK2 P24941 1/20 0.38
AKT1 P31749 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
RPS6KA3 P51812 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22284254 1.00 PHGDH (0.39) PHGDHKMT2ANPSR1MAPK1ROCK2
SCHEMBL22284303 0.95 ROCK2 (0.42) KMT2ANPSR1MAPK1ROCK2RPS6KA5
SCHEMBL22284300 0.95 ROCK2 (0.42) KMT2ANPSR1MAPK1ROCK2RPS6KA5
SCHEMBL30554287 0.95 ROCK2 (0.42) KMT2ANPSR1MAPK1ROCK2RPS6KA5
SCHEMBL22284368 0.93 BACE1 (0.37) MAPK1ROCK2RPS6KA5MAP4K4CDK1
SCHEMBL22284367 0.93 BACE1 (0.37) MAPK1ROCK2RPS6KA5MAP4K4CDK1
SCHEMBL22284157 0.93 PDE2A (0.44) MAPK1ROCK2RPS6KA5MAP4K4CDK1
SCHEMBL30554296 0.93 PDE2A (0.44) MAPK1ROCK2RPS6KA5MAP4K4CDK1
SCHEMBL22284158 0.93 PDE2A (0.44) MAPK1ROCK2RPS6KA5MAP4K4CDK1
SCHEMBL30554292 0.93 BACE1 (0.37) MAPK1ROCK2RPS6KA5MAP4K4CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF MAPK1, MAPK11, MAPK14 PHGDH 599/4885KMT2A 3774/4885NPSR1 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.